Adenosine deaminase (ADA) deficiency causes severe combined immune deficiency (SCID) by interfering with the metabolism of deoxyadenosine, which is toxic to T lymphocytes at all stages of differentiation. Enzyme replacement with polyethylene glycol-modified ADA (PEG-ADA) has been previously shown to correct deoxyadenosine metabolism and improve mitogen-induced T lymphocyte proliferation. We studied the biochemical and immunologic effects of PEG-ADA in two infants with ADA-deficient SCID. While in a catabolic state, higher doses of PEG-ADA than previously described were required to normalize deoxyadenosine metabolism. After biochemical improvement, the patients recovered immune function in a pattern similar to that observed in normal thymic ontogeny and in patients with immunological reconstitution after bone marrow transplantation. Immune reconstitution was marked by the sequential appearance in the peripheral blood of phenotypic T lymphocytes corresponding to successive stages of thymic differentiation. Functional reconstitution was marked by the successive appearance of mitogen responses dependent on exogenous in vitro IL-2, mitogen responses not requiring exogenous IL-2, antigen-specific responses dependent on exogenous IL-2, and finally, antigen-specific responses not requiring exogenous IL-2. Natural killer function was tested in one patient and normalized with PEG-ADA therapy. Optimal PEG-ADA therapy appears to normalize thymic differentiation in ADA-deficient SCID, resulting in normal antigen-specific immune function. (J. Clin. Invest. 1993. 92:596-602.)
Introduction
In severe combined immunodeficiency disease (SCID),' T and B lymphocyte dysfunction predisposes to life-threatening 1. Abbreviations used in thispaper: ADA, adenosine deaminase; dAdo, deoxyadenosine; dAXP, deoxyribonucleotide; EC, effector cells; IVIg, intravenous immunoglobulin; NK, natural killer; PEG-ADA, polyethinfections ( 1 ) . The etiology ofSCID in most cases is unknown, but 20% of patients are deficient in adenosine deaminase (ADA), an enzyme expressed at very high levels in immature thymocytes (2) . Toxicity of the ADA substrate, deoxyadenosine (dAdo) , is thought to be responsible for the profound T lymphopenia of ADA-deficient infants and fetuses (3) . T lymphocytes at all stages of maturation are sensitive to dAdo, so that the exact stage at which T lymphocyte development is interrupted and the ultimate nature of the responsible lesion are unclear.
Since 1986, enzyme replacement therapy for ADA deficiency has been possible with intramuscular injections ofpurified bovine ADA, modified with polyethylene glycol (PEG) to prolong its circulating life and reduce immunogenicity (4, 5) . PEG-modified ADA (PEG-ADA) has been used in patients who lack an HLA-identical sibling bone marrow donor or in whom transplantation of T cell-depleted, HLA-haploidentical (parental) marrow had been ineffective or was considered an unacceptable alternative. A fundamental difference in the outcome oftherapy with PEG-ADA and haploidentical transplantation is that PEG-ADA patients develop autologous T lymphocyte function, while the T lymphocytes oftransplanted patients are exclusively of donor origin.
Since untreated ADA-deficient SCID patients have small numbers of T lymphocytes, it has not been possible to determine whether T lymphocytes that appear after PEG-ADA therapy result from the clonal expansion ofpre-existing T lymphocytes that escaped intrathymic selection and metabolic death due to ADA deficiency or whether PEG-ADA permits the differentiation of T lymphocytes de novo from immature thymic precursors. To determine the origin of T lymphocytes after PEG-ADA therapy, we examined the pattern of immunological reconstitution and antigen-specific function of T lymphocytes of two PEG-ADA-treated patients.
Methods

Biochemical studies
Heparinized venous blood was separated into plasma and packed red cell fractions, which were frozen until analysis. Plasma levels of ADA activity, levels oftotal erythrocyte adenine ribo-and deoxyribonucleotides (dAXP) and erythrocyte levels of S-adenosylhomocysteine hydrolase (SAHase) activity were determined as previously de- scribed (6) (7) (8) (9) (normal, 8-84) . Red blood cell ADA activity was absent (normal, 33-100 umol/h per g hemoglobin), diagnostic of ADA deficiency.
The patient did not have a histocompatible sibling donor. Compromised pulmonary status and active parainfluenza infection increased his risks ofmorbidity and mortality from pretransplant ablative chemotherapy and T lymphocyte-depleted haploidentical bone marrow transplantation. Because of these risks, enzyme replacement therapy with PEG-ADA was instituted. During the period of study PEG-ADA was administered once or twice weekly by intramuscular injections, as described in Results.
Parainfluenza type 2 was treated with aerosolized ribavirin and QOD intravenous immunoglobulin (IVIg), but respiratory function continued to deteriorate during the first 3 wk oftherapy. From weeks 3 to 6 of PEG-ADA therapy, the patient required mechanical ventilatory assistance with endotracheal delivery ofthe ribavirin. After week 6, his pulmonary status had improved so that mechanical ventilation was not required, although he was still dependent on supplemental oxygen until week 27. Cultures for parainfluenza type 2 remained positive until week 12 of PEG-ADA therapy. Ribavirin was discontinued at week 17 without recurrence of parainfluenza. The patient was discharged from the hospital 22 wk after starting PEG-ADA therapy. After week 25 he received 30 mg/kg PEG-ADA once weekly and IVIg once monthly. After 1 yr of PEG-ADA therapy, he was shown to have a normal humoral response to OX 174, and IVIg was discontinued. He has had no new opportunistic infections, is now growing normally, and no longer requires supplemental oxygen.
Patient 2. Patient 2 is the full-term product of an uncomplicated pregnancy in a 14-yr-old GlPl woman. She is the product ofa consanguineous union between the mother and a maternal uncle. She presented to Children's Hospital San Diego at 3.5 mo ofage with failure to thrive and a history of diarrhea. She had an episode of bronchitis, which was treated with ampicillin, 3 wk before admission. The patient's physical examination was remarkable only for evidence of failure to thrive. Less than 1% of the peripheral blood lymphocytes were CD3+. Serum Ig levels were diminished: IgG = 108 mg/dl, IgM < 7 mg/dl, IgA < 7 mg/dl. There was no proliferative response to PHA. Despite one immunization with tetanus toxoid, there was no protective titer to tetanus. Red blood cell ADA activity was absent.
On the 12th hospital day the patient developed fever and tachypnea. Bronchoalveolar lavage fluid grew Pseudomonas but was negative for Pneumocystis carindi or any virus. She responded to tobramycin and ceftazidime. She received intravenous hyperalimentation, IVIg twice weekly, and prophylactic trimethoprim-sulfamethoxazole during hospitalization.
On day 14 ofhospitalization, she was started on twice weekly injections of PEG-ADA, as described in Results. 5 wk after beginning PEG-ADA therapy, rotavirus infection was demonstrated in the patient's stool. Rotavirus cleared by week 6 ofPEG-ADA therapy. The patient's immunologic function and nutritional status improved so that she could be discharged from the hospital by week 17 of PEG-ADA therapy. She is presently 11 mo of age with normal growth and development. She continues to receive monthly IVIg but has been hospitalized for only 2 Weeks Figure 1 . Normalization of plasma ADA activity, RBC dAXP, and RBC SAHase levels in patient 1 during PEG-ADA therapy. During the first 6 wk of therapy, the PEG-ADA dose was 30 U/kg actual body weight. The arrow at top left indicates when the PEG-ADA dose was increased to 30 U/kg ideal body weight twice weekly. The arrow at top right indicates when the PEG-ADA dose was decreased to 30 U/kg ideal body weight once weekly.
tively low level for ADA-deficient SCID, reflecting blood transfusion) to 9 nmol/ml packed cells (normal, < 1-2 nmol/ml). Erythrocyte SAHase activity increased from 0.37 to 1-1.6 nmol/h per mg protein (mean, 1.26), only 30% of normal (4.2±1.9 nmol/h per mg).
During week 6, plasma ADA declined to 6.9 Mmol/h per ml and red blood cell (RBC) SAHase fell to 0.56 nmol/h per mg. The dose of PEG-ADA was increased to twice weekly injections of 30 U/kg ideal body weight (the 50th percentile of weight for the patient's age). Between weeks 7 and 25, plasma ADA averaged 47.9±11.7 ,imol/h per ml and RBC dAXP fell to 1-3 nmol/ml packed cells (Fig. 1) During the first weeks ofPEG-ADA therapy, no immediate change in the phenotype was observed. Beginning at week 10 in patient 1 and week 5 in patient 2, the number of CD3"i" lymphocytes increased (Figs. 2, 3 A, and 4 A) . The CD3dim lymphocytes were CD4-and CD8-. After the appearance of CD3d"' cells, there was a transient increase in the number of CDl + cells. CDl + cells were detected from weeks 10 to 12 in patient 1 and at week 9 in patient 2 (Figs. 3 A and 4 A) . The CDl + cells coexpressed CD3, CD4, and CD8.
T lymphocytes bearing the mature phenotype of CD33b'it CD4+ or CD3b'igt CD8+ appeared only after the increases in CD3dlm and CDl+ populations (Figs. 2, 3 A, and 4 A) . Dual fluorescence analysis demonstrated that the CD3t iO't lymphocytes expressed either CD4 or CD8. Dual analysis with antibodies directed against CD4 and CD8 showed that the T lymphocytes did not coexpress both antigens. In patient 1, the first CD3b1`0t cells observed (before week 14) predominantly ex- Fig.  3 B) . For patient 2, a proliferative response dependent on exogenous IL-2 was present at week 9 (Acpm = 10,607±711, S.I. =23) (Fig. 4 B) .
Proliferative responses to PHA that were independent of exogenous IL-2 developed after the IL-2-dependent responses. 3 wk after developing an IL-2-dependent response, patient 1 had proliferative responses to PHA without exogenous IL-2 (Acpm = 15,640±1,441, S.I. = 25), although the PHA response was still augmented by exogenous IL-2 (Acpm = 25,573±3,193, S.I. = 45). A proliferative response to PHA, which was not augmented by exogenous IL-2, was demonstrable 6 wk later. The PHA response without exogenous IL-2 continued to increase and was normal (Acpm > 75,000) by week 28 (Fig. 3 B) . 2 wkafterthe development ofan IL-2-dependent response, patient 2 had a normal proliferative response to PHA (Acpm = 116,571+11,543, S.I. = 101), which was not dependent on, or augmented by, exogenous IL-2 (Fig. 4 B) .
Antigen-specific responses
The patients were tested for antigen-specific T lymphocyte proliferation after immunization with tetanus toxoid. In patient 1, an in vitro proliferative response to tetanus toxoid, which was dependent on exogenous IL-2, was demonstrable by week 19,2 wk after immunization (Acpm = 21,164±5,333, S.I. = 10) (Fig. 3 C) ( 12, 13 The phenotype of the patients' T lymphocytes after PEG-ADA therapy is consistent with the maturation of functional T lymphocytes from immature thymic progenitors. After normalization of the plasma ADA activity and metabolic parameters, the number of CD3'm lymphocytes increased. Such CD3dim T lymphoid progenitors represent an early stage ofthymic maturation (14) . Although most CD3dim thymic progenitors are also CD4+ and CD8+, CD3 dim CD4-CD8-cells, like those observed in the patients, are also present in normal thymus ( 15, and Weinberg, K. I., unpublished observations). After the appearance of CD3dim T lymphocytes, there was a wave of lymphocytes expressing the CDl antigen, which is a marker of an intermediate, possibly functionally inert, stage of thymic ontogeny ( 16) . CD 1+ cells are found in newborn cord blood and bone marrow transplant recipients in whom T lymphocyte maturation is occurring ( 17, 18) . Lymphocytes bearing a mature T lymphocyte phenotype, i.e., CD3b'gh' CDl-CD4+ CD8-or CD3b ght CDl -CD4-CD8+, did not appear until 3 mo after beginning PEG-ADA therapy. As in normal thymic maturation, the first mature CD3b br*1 cells in patient 1 added to the cultures. The IL-2 dependence indicates that T lymphocytes capable of expressing the IL-2 receptor were present but that IL-2 production was absent. After the development ofan IL-2-dependent mitogen response, PHA-induced proliferation in the absence of exogenous IL-2 could be detected, demonstrating normal in vitro production of IL-2. The PHA response in the absence of exogenous IL-2 indicates that both IL-2-dependent and IL-2-producing T lymphocytes were present. A similar pattern of initial IL-2 deficiency has been described in the immune reconstitution of bone marrow transplant recipients (22, 23) .
The development of antigen-specific T lymphocyte responses in the PEG-ADA-treated patients is similar to that seen in patients after bone marrow transplantation or in normal ontogeny (22) (23) (24) . Mitogen responsiveness normally precedes the development of antigen-specific responses. In patient 1, PHA-responsive T lymphocytes were followed by antigen-specific responses to tetanus and candida, which were dependent on exogenous IL-2. Patient 2 was immunized with tetanus toxoid later than patient 1. No early IL-2-dependent phase was observed in tetanus responsiveness. The candida response of patient 2 was initially IL-2 dependent. The need for exogenous IL-2 indicates that relatively normal numbers of antigen-specific IL-2-dependent T lymphocytes are present, but that a deficiency of IL-2-producing antigen-specific T lymphocytes exists. Several weeks later, antigen-specific proliferative responses, which did not require exogenous IL-2, were present. It is not known whether the suboptimal IL-2 production is due to a quantitative decrease in IL-2-producing cells or to a qualitative defect in IL-2 production. The results with exogenous IL-2 suggest that therapy with recombinant IL-2 might be useful in PEG-ADA recipients who have developed IL-2-dependent cells but who still lack adequate IL-2 production.
The eradication of infection coincided with the appearance of mitogen-responsive IL-2-dependent T lymphocytes. After PEG-ADA therapy, patient 1 had normal NK function. It is possible that NK activity was partly responsible for the clearance ofthe virus. NK cells have been shown to be important in the control of other viral infections (25) . The patient's ability to tolerate withdrawal of ribavirin therapy is almost certainly the result ofdevelopment of antigen-specific responses to parainfluenza.
The studies of these two patients illustrate that PEG-ADA administration must be individualized, based on monitoring of both plasma ADA activity and metabolic abnormalities. Although erythrocyte dAXP declined substantially in the early weeks of patient l's therapy, trough plasma ADA activity was not maintained above 12 ,gmol / h per ml, a level used as a guide to therapy in previous patients (4, 12, 26, 27 This study demonstrates that antigen-specific T lymphocyte function can be successfully achieved in ADA-deficient SCID after optimal PEG-ADA therapy. Antigen-specific T lymphocyte responses, as described in this report, have developed in -40% of patients treated with PEG-ADA (12, 13) .
Further studies of other PEG-ADA-treated patients will be required to determine which factors predict a complete response to PEG-ADA treatment. The quality ofimmune reconstitution is comparable to that achieved after haploidentical T lymphocyte-depleted bone marrow transplantation (24) . There may be better recovery of humoral immune function in patients who respond to PEG-ADA than in those who show stable engraftment after haploidentical marrow transplantation (28) .
Unlike bone marrow transplantation, PEG-ADA therapy is not complicated by the risks of cytoreductive chemotherapy, which is frequently required for transplantation in ADA deficiency (1 1, 29) . As in T lymphocyte-depleted bone marrow transplants, the antigen-specific T lymphocytes appear to develop from immature thymic progenitors. Thus, PEG-ADA therapy of SCID is a model for the study of postnatal thymic differentiation.
